Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Nektar Therapeutics’s 10-Q, filed May 8, 2026.
- Filed
- May 7, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-212596
| Line item | Three Months Ended March 31, | Three Months Ended March 31, | Three Months Ended March 31, |
|---|---|---|---|
| Total revenue | 10,861 | 10,460 | |
| Operating costs and expenses: | |||
| Research and development (including $1,708 and $208 for the three months ended March 31, 2026 and 2025, respectively, from a related party) | 35,680 | 30,480 | |
| General and administrative | 13,439 | 24,346 | |
| Restructuring and impairment | 796 | 169 | |
| Total operating costs and expenses | 49,915 | 54,995 | |
| Loss from operations | (39,054) | (44,535) | |
| Non-operating income (expense): |
Item 1. Condensed Consolidated Financial Statements—Unaudited:
FAQ
- What is Nektar Therapeutics's G&A?
- Nektar Therapeutics (NKTR) reported G&A of $13.44M in Q1 2026.
- How has Nektar Therapeutics's G&A changed year-over-year?
- Nektar Therapeutics's G&A decreased by 44.8% year-over-year, from $24.35M to $13.44M.
- What is the long-term trend for Nektar Therapeutics's G&A?
- Over 4 years (2021 to 2025), Nektar Therapeutics's G&A has grown at a -13.5% compound annual growth rate (CAGR), from $122.84M to $68.67M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Nektar Therapeutics's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude